Staphylococcus pseudintermedius

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Staphylococcus pseudintermedius is a Gram-positive, non-spore-forming, facultatively anaerobic, non-motile, coccus bacterium. It has been detected in at least 2 gut microbiome compilation studies or metastudies. The DNA G+C content is 38%. Staphylococcus pseudintermedius is probably a rare gut coloniser. (Devriese2005)



  • This organism has been recovered from human faeces, clinical sources (wound, blood, infection - CCUG) animal lesions. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: human and animal pathogen). It is an opportunistic pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Devriese2005);
    Character Response
  • Substrates hydrolysed or digested:
  • DNA;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; mannose; ribose; lactose; maltose; sucrose; trehalose; N-Ac glucosamine;
  • Active enzymes:
  • arginine dihydrolase; catalase; coagulase; DNase; β-galactosidase; β-glucosidase; pyrrolidine arylamidase; urease;
    • SPECIAL FEATURES (Devriese2005);
    Character Response
  • ✓
  • VP test:
  • active
  • ✓
  • ONPG test:
  • active
  • Haemolysis:
  • beta
  • ✓
  • Nitrate:
  • reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Devriese2005); (Goldstein2018); (Goldstein2012);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; ertapenem;
  • Cephalosporins:
  • cefazolin;
  • Macrolides:
  • azithromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline; tigecycline;
  • Heterocycles:
  • trimethoprim-sulfamethoxazole;
  • Miscellaneous antibiotics:
  • novobiocin;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Bacilli Order:  Bacillales Family:  Staphylococcaceae Genus:  Staphylococcus Gram stain:  + O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Sessile Morphology:  Coccus Pigment:  neg
    Health:  Unknown
    Source:  human faeces, clinical sources (wound, blood, infection - CCUG) animal lesions
    DNA G+C(%):  38
    		DNA:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  neg L-Arabinose:  neg Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  + D-Lyxose:  neg Rhamnose:  neg Ribose:  + Sorbose:  neg D-Tagatose:  neg Xylose:  neg L-Xylose:  neg Cellubiose:  neg Lactose:  + Maltose:  + Melezitose:  neg Melibiose:  neg Sucrose:  + Trehalose:  + Turanose:  w Amygdalin:  neg Aesculin:  neg Glycogen:  neg Inulin:  neg Starch:  neg Adonitol:  neg L-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  w Inositol:  neg Mannitol:  w Sorbitol:  neg Xylitol:  neg Arbutin:  neg Gluconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg Me-α-D-Glc:  neg Me-Xyloside:  neg NAc-α-GA:  + Salicin:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  + Urease:  + Coagulase:  + β-Galactosidase:  + β-Glucosidase:  + β-Glucuronidase:  neg ArgDH:  + PyrrolidAA:  + DNAse:  +
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.06), MIC90: S(0.06, RNG: (0.06–2)
    amp-sulb:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.03–1)
    ertapenem:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.06–1)
    cefazolin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06–16)
    azithromycin:  S(MIC50): 2, MIC90: 2, RNG: (1–4)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.03–2)
    minocycline:  S(MIC50): 0.03), MIC90: S(0.03, RNG: (0.03–4)
    tetracycline:  S(MIC50): 0.125), MIC90: S(0.125, RNG: (0.125–32)
    tigecycline:  S(MIC50): 0.06), MIC90: S(0.06, RNG: (0.06–.06)
    SXT:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06–0.25)
    novobiocin:  Sens

    References

    SPECIFIC REFERENCES FOR STAPHYLOCOCCUS PSEUDINTERMEDIUS
  • Devriese2005 - Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals.
  • Cole2019 - Modernising Medical Microbiology Consortium. Draft Genome Sequences of 64 Type Strains of 50 Species and 25 Subspecies of the Genus Staphylococcus Rosenbach 1884.
  • Goldstein2018 - Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates.
  • Goldstein2012 - Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR STAPHYLOCOCCUS PSEUDINTERMEDIUS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Forster2019 - A human gut bacterial genome and culture collection for improved metagenomic analyses.
  • ...............................
    • Added: December 15, 2021